A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

Active:	Yes
Cancer Type:	Multiple Myeloma	NCT ID:	NCT06413498
Trial Phases:	Phase III	Protocol IDs:	KT-US-679-0788 (primary) NCI-2024-05712 2024-511188-26
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Kite, A Gilead Company
NCI Full Details:	http://clinicaltrials.gov/show/NCT06413498

Summary

The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene
autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory
multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38
monoclonal antibody and an immunomodulatory drug.

The primary objective of this study is to compare the efficacy of anitocabtagene
autoleucel versus SOCT in participants with RRMM as measured by progression-free survival
(PFS) per blinded independent review committee (IRC).

Objectives

After completing the treatment period, all participants who will receive anitocabtagene
autoleucel, will be followed in the post-treatment follow-up period. Thereafter,
participants will transition to a separate long-term follow-up study (KT-US-982-5968) to
continue follow-up out to 15 years.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.